<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7396720\results\search\testTrace\results.xml">
  <result pre="SARS-CoV-2 [20]. Similarly, a SARS-CoV RBD-specific antibody failed to block" exact="infection" post="mediated by the S protein of SL-CoVâ€&quot;SHC014 [22], which"/>
  <result pre="ZIKV envelope protein was demonstrated in 2017 to potently inhibit" exact="infection" post="byÂ ZIKV and other flaviviruses in vitro [29], implying"/>
  <result pre="viruses competitively bind to viral HR1 and effectively inhibit viral" exact="infection" post="[22]. Therefore, HR1 is a promising target for the"/>
  <result pre="SARS-CoV-2 mediates receptor recognition, cell attachment, and fusion during viral" exact="infection" post="[16, 20, 21, 31â€&quot;33]. The trimer of the S"/>
  <result pre="protein The fundamental role of the S protein in viral" exact="infection" post="indicates that it is a potential target for vaccine"/>
  <result pre="or in combination with other nAbs, for the prevention and" exact="treatment" post="of SARS-CoV-2 infection [57]. A mAb targeting S1 prepared"/>
  <result pre="with other nAbs, for the prevention and treatment of SARS-CoV-2" exact="infection" post="[57]. A mAb targeting S1 prepared from immunized transgenic"/>
  <result pre="IPB02, potently inhibits SARS-CoV-2 S protein-mediated cellâ€&quot;cell fusion and pseudovirus" exact="infection" post="[65]. In addition to peptide fusion inhibitors, nelfinavir mesylate"/>
  <result pre="entry via endocytosis. E-64d, an inhibitor of cathepsin L, blocks" exact="infection" post="with SARS-CoV and SARS-CoV-2 PsV [68â€&quot;70]. Future trials with"/>
  <result pre="describes the use of furin or its inhibitors in the" exact="treatment" post="of diseases, and some furin inhibitors that have been"/>
  <result pre="human mAbs. Furthermore, atomic-level details will enable the design and" exact="screening" post="of small molecules that inhibit fusion. Since SARS-CoV-2 and"/>
  <result pre="fusion and can potentially be used for the prevention and" exact="treatment" post="of infection. It is worth mentioning that EK1C4, which"/>
  <result pre="Mol Biol2015128212325720466 10.MorseJSLalondeTXuSLiuWRLearning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChembiochem202021730832022370"/>
  <result pre="fusion inhibitorsLancet20043639384715043961 29.YuYDengYQZouPWangQDaiYYuFet al.A peptide-based viral inactivator inhibits Zika virus" exact="infection" post="in pregnant mice and fetusesNat Commun201781567228742068 30.WeissenhornWDessenACalderLJHarrisonSCSkehelJJWileyDCStructural basis for"/>
  <result pre="vulnerability. bioRxiv. 2020. 10.1101/2020.05.08.083964. 64.XiaSLiuMQWangCXuWLanQSFengSLet al.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse modelVirus Res201722871327840112 69.HuangICBoschBJLiWHFarzanMRottierPMChoe H. SARS-CoV, but"/>
 </snippets>
</snippetsTree>
